Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Pressemeddelelse

Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) announces its first day of trading on Nasdaq First North under its new company name

Perpetua Medical

Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) will start trading on Nasdaq First North Stockholm under the ticker PERP B today.

Following the extraordinary general meeting's resolution to adopt a new articles of association, the Swedish Companies Registration Office (Swe: Bolagsverket) has approved the company's submission, after which Nasdaq has approved the application to change the name of the company. The first day of trading will take place today, April 23, 2024, under the ticker PERP B.

The new name reflects the company's ambition to be a long-term owner of profitable companies operating in the healthcare sector. The businesses and the decision-making are intended to take place in the independent subsidiaries.

Erik Hedlund, Chairman of the Board and main shareholder of Perpetua Medical AB, comments: "We are working intensively together with the incoming CEO to build a sustainable business with a new strategy. We are in ongoing discussions with several companies within the healthcare sector that are profitable today and have growth potential.

Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.